# GSK vs Moderna: valuation, size and margins compared

URL: https://funkfolio.com/compare/gsk-vs-mrna

> GSK ($98.7B, P/E 17.2) and Moderna ($83.7B) side by side: market value, valuation, margins, balance sheet, one-year price change and superinvestor holders.

---

## GSK vs Moderna

GSK (GSK), health care, and Moderna (MRNA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

GSK is worth $98.7B on the stock market and Moderna $83.7B: GSK is valued at 18% more. GSK's operating margin in its latest fiscal year was 24.3% and Moderna's -158%. Over the past year GSK's share price has moved +6.42% and Moderna's +764%.

### Key facts

- **GSK market value:** $98.7B
- **Moderna market value:** $83.7B
- **GSK P/E:** 17.2
- **GSK revenue:** $43.4B FY to 2025-12-31
- **Moderna revenue:** $1.9B FY to 2025-12-31
- **Superinvestors holding both:** 0

Market values as of 18 Nov 2026, 09:47 UTC.

GSK vs Moderna: every measure side by side

| Measure | GSK | Moderna |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United Kingdom | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $98.7B higher | $83.7B lower |
| Revenue | $43.4B higher | $1.9B lower |
| Earnings | $7.6B higher | -$2.8B lower |
| Employees | 66,841 higher | 4,700 lower |
| Total assets | $81.1B higher | $12.3B lower |
| Valuation |  |  |
| P/E | 17.2 | — |
| P/S | 2.3 lower | 43.0 higher |
| P/B | — | 12.2 |
| Dividend yield | — | 0.00% |
| Profitability |  |  |
| Operating margin | 24.3% higher | -158% lower |
| Balance sheet |  |  |
| Net assets | $21.7B higher | $8.7B lower |
| Total liabilities | $59.9B higher | $3.7B lower |
| Total debt | $19.2B higher | $590M lower |
| Cash on hand | $4.5B higher | $2.6B lower |
| Price change |  |  |
| Today | -2.32% higher | -3.93% lower |
| 1 year | +6.42% lower | +764% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: GSK 103.6, Moderna 835.2.

- GSK (GSK)
- Moderna (MRNA)

GSK and Moderna share prices over one year, rebased to 100: GSK ends at 103.6, Moderna at 835.2.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | GSK | MRNA |
| --- | --- | --- |
| Nov 28, 2025 | 100.7 | 104.9 |
| Dec 31, 2025 | 103.2 | 119.1 |
| Jan 30, 2026 | 108.6 | 178.0 |
| Feb 27, 2026 | 124.4 | 216.4 |
| Mar 31, 2026 | 116.1 | 205.2 |
| Apr 30, 2026 | 110.1 | 185.5 |
| May 29, 2026 | 106.3 | 190.6 |
| Jun 30, 2026 | 110.3 | 282.8 |
| Jul 31, 2026 | 108.8 | 221.4 |
| Aug 31, 2026 | 105.7 | 566.8 |
| Sep 30, 2026 | 101.3 | 777.7 |
| Oct 30, 2026 | 104.2 | 895.5 |
| Nov 17, 2026 | 103.6 | 835.2 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (0)

None of the tracked investors.

#### GSK only (11)

- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.1%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.9%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.8%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.5%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.4%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1%

#### Moderna only (2)

- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 2.1%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.4%

Percentages are each holding's share of that investor's reported portfolio. [Who owns GSK](https://funkfolio.com/stock/GSK/superinvestors) · [Who owns MRNA](https://funkfolio.com/stock/MRNA/superinvestors)

### More on GSK

- [GSK (GSK) stock page](https://funkfolio.com/stock/GSK)
- [GSK market cap](https://funkfolio.com/stock/GSK/market-cap)
- [GSK revenue](https://funkfolio.com/stock/GSK/revenue)
- [GSK P/E ratio](https://funkfolio.com/stock/GSK/pe-ratio)
- [GSK operating margin](https://funkfolio.com/stock/GSK/operating-margin)
- [GSK total debt](https://funkfolio.com/stock/GSK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Moderna

- [Moderna (MRNA) stock page](https://funkfolio.com/stock/MRNA)
- [Moderna market cap](https://funkfolio.com/stock/MRNA/market-cap)
- [Moderna revenue](https://funkfolio.com/stock/MRNA/revenue)
- [Moderna P/E ratio](https://funkfolio.com/stock/MRNA/pe-ratio)
- [Moderna operating margin](https://funkfolio.com/stock/MRNA/operating-margin)
- [Moderna total debt](https://funkfolio.com/stock/MRNA/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### GSK against its closest peers

- [GSK vs HCA Healthcare](https://funkfolio.com/compare/gsk-vs-hca)
- [GSK vs CVS Health](https://funkfolio.com/compare/cvs-vs-gsk)
- [GSK vs Regeneron Pharmaceuticals](https://funkfolio.com/compare/gsk-vs-regn)

#### Moderna against its closest peers

- [Moderna vs CVS Health](https://funkfolio.com/compare/cvs-vs-mrna)
- [Moderna vs Sanofi](https://funkfolio.com/compare/mrna-vs-sny)
- [Moderna vs HCA Healthcare](https://funkfolio.com/compare/hca-vs-mrna)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, GSK or Moderna?**

By market value, GSK is the larger: $98.7B against $83.7B for Moderna. By revenue in its latest fiscal year, GSK is the larger: $43.4B against $1.9B for Moderna.

**Which has the higher operating margin?**

GSK: 24.3%, against -158% for Moderna. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

GSK: $19.2B, against $590M for Moderna. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both GSK and Moderna?**

None of the tracked superinvestors holds both in their latest 13F filing. 11 hold GSK and 2 hold Moderna.

### Cite this page

Funkfolio, “GSK vs Moderna”, data as of 18 November 2026. https://funkfolio.com/compare/gsk-vs-mrna

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
